posted
DNAPrint genomics, Inc., applies proprietary human genome technology to develop pharma-predictive tests for matching patients with drugs based on genetic makeup. It has also developed genomics products for law enforcement forensics and consumer markets. DNAP's business is focused on three segments: pharmacogenomics, forensics, and genealogy, all based on core technology for targeting single nucleotide polymorphisms (SNPs)
DNAPrint(tm) genomics, Inc. (OTCBB:DNAG) today announced the completion of initial research for the production of PT-401, a more powerful version of the anemia drug Erythropoietin (EPO), which has advanced into the preclinical development stage for the Company's first pharmaceutical product.
"Our research surveyed several potential host cells for the production of PT-401," stated Hector Gomez, M.D., Ph.D., Chairman and Chief Medical Officer of DNAPrint genomics. "We have selected one that the research indicates will provide superior glycosylation, which is critical for the processing of PT-401. We anticipate that this will lead to greater therapeutic efficacy and later on will be beneficial to expediting regulatory approval. In addition, we have optimized the structure of the gene encoding PT-401, thus providing excellent production efficiency and an optimal structure/activity profile of the active compound. Our production schedule remains on target."
DNAPrint(tm) obtained an exclusive worldwide license from Harvard Medical School's Beth Israel Deaconess Medical Center (BIDMC) in February 2005 for the development of a "Super" EPO, a more potent and longer acting form of Erythropoietin (EPO), which has a worldwide market exceeding $10 billion and which is growing at an average annual rate of 21%. Production of a Super EPO dimer is central to DNAPrint's overarching strategy to utilize recent genomics and chemistry advances to develop next-generation test/drug combinations called "Theranostics," which maximize efficacy and minimize side effects by tailoring and customizing medication for specific individuals and well-defined population sectors. In June 2005, DNAPrint selected Proteos, Inc., to handle pre-clinical analysis of PT-401 and to manufacture the first batch of the new drug.
IP: Logged |
posted
yes, but it's having a tough time breaking through .0198 now that DOMS has joined the ask, If we can rise through, charts indicate no real resistance 'til .036. (as stated previously)
posted
DNAPrint genomics Forensics Technology Assists Police in Identifying Suspect in California Double Murder 10/3/2005 7:00:43 AM SARASOTA, Fla., Oct 3, 2005 (PRIMEZONE via COMTEX) -- DNAPrint genomics, Inc. ( DNAG ) today confirmed that its DNAWITNESS forensics technology narrowed down a list of potential suspects during a police investigation that led to an arrest in the murder of two women in Napa, Calif.
The brutal stabbings of Leslie Ann Mazzara and Adriane Michelle Insogna, both 26, in a home they shared in the Northern California community, had stumped police for nearly 11 months because the women had no known enemies and there was no apparent motive. Police had speculated that the killer knew one or both of the victims.
Being held in custody was a man identified by authorities as Eric Matthew Copple, 26, of Napa. Police conducted more than 1,300 interviews during the investigation and collected DNA samples from 218 individuals, all men who had social or work contact with all three roommates who lived in the home. A third woman escaped unharmed during the Nov. 1, 2004, attack and called police.
The California Department of Justice Crime Lab and DNAPrint genomics previously determined that an analysis of blood samples collected at the crime scene indicated that the suspect was a male. Forensic evidence also pointed to a killer who smoked Camel Turkish Gold cigarettes, a hybrid of the popular cigarette brand. NapaPolice issued a statement to the media on Sept. 22, 2005, saying that DNAPrint genomics' forensics laboratory had further determined that the ancestry of the person of interest was white with 96% Northern European ancestry and 4% Southeastern European.
"We received a DNA sample from the Napa Police on Nov. 23, 2004 and returned the results of our DNAWITNESS analysis two days later," stated DNAPrint genomics President and Chief Executive Officer Richard Gabriel. "More recently, the case was revisited when DNAPrint was asked to analyze the sample with our EUROWitness technology to further refine the information. With information from DNAPrint, the Napa Police Department did a media release describing a white male adult who smokes or did smoke Camel Turkish Brand Cigarettes."
The San Francisco Chronicle newspaper reported that Napa Police Department Investigations Bureau Commander Jeff Troendy confirmed that DNA-related evidence and the media release led to the arrest of Copple. Troendy was quoted as saying, "The media release last week helped us get to this point, sometimes things happen very quickly."
About DNAPrint genomics, Inc.
DNAPrint genomics, Inc. ( www.dnaprint.com) is a developer of genomics-based products and services focused on drug development, pharmacogenomic diagnostic tests, forensics technology and consumer genetic tests. DNAPrint's family of products for the law enforcement forensics and consumer markets include DNAWitness RETINOME (a predictive test for inferring eye color from a DNA sample), ANCESTRYbyDNA, and EURO-DNA. Recently announced and as a part of the Company's Trace Genetics acquisition, DNAWitness-Y and DNAWitness-Mito are two new tests that can be used as an identification
IP: Logged |
posted
Updated: 07:14 AM EDT DNAPrint genomics Forms Pharmaceutical Subsidiary
SARASOTA, FL -- (MARKET WIRE) -- 10/12/05 -- DNAPrint(TM) genomics, Inc. (OTC BB: DNAG), a developer of genomics-based products and services, today announced that it has established DNAPrint Pharmaceuticals, Inc., a new wholly owned pharmaceutical subsidiary focused on personalized medicine.
"Since its inception, DNAPrint genomics successfully has leveraged its broad-based expertise in genomics into three business segments -- ancestry for the consumer market, forensics technology for law enforcement and pharmacogenomics -- personalized medicine based on a patient's DNA," stated Company President and Chief Executive Officer Richard Gabriel. "With our ANCESTRYbyDNA(TM) and DNAWITNESS(TM) technologies serving as a foundation for the Company's business, DNAPrint Pharmaceuticals is being targeted as the engine for further expansion and growth. We now have the corporate flexibility to concentrate on the pharmaceutical products we are currently licensing or have under development. To further finance this effort we will also be seeking funding for DNAPrint Pharmaceuticals."
"We are at the forefront in the development of personalized medicines and genomics-based pharmaceuticals, the Company's main focus," stated Hector J. Gomez, M.D., Ph.D., DNAPrint's Chairman and Chief Medical Officer, who will head the new subsidiary's day-to-day operations. "We believe that test/drug combinations called 'theranostics' are the wave of the future and that our new DNAPrint Pharmaceuticals subsidiary affirms the Company's commitment to the development of these products."
Data Monitor and the Pharmaceutical Manufacturer's Association expect the worldwide pharmaceutical market to more than triple over the next 10-15 years to an estimated trillion dollars a year, driven primarily by a flood of new drug targets and the increase in the U.S. demand for drug treatments as the baby boomer population ages. Many of these targets were identified through genomics, opening the way for DNAPrint genomics to develop theranostic drugs to reduce side effects and provide greater efficacy through accompanying genomic response tests designed to ensure that patients receive the appropriate medication and dosage.
DNAPrint took a significant step in pharmaceutical development in July 2005 by acquiring an 18% stake in the German pharmaceutical company Biofrontera, which also has a number of compounds under development. Biofrontera is in Phase II clinical trials for its lead product, an anti-itch compound for chronic Urticaria, or chronic itching. It also has a Phase II clinical trial compound for pre-cancerous skin lesions. In addition, Biofrontera has advanced several compounds to pre-clinical development, including a novel prophylactic migraine treatment.
DNAPrint's first test/drug combination is PT-401, being developed in collaboration with Harvard Medical School's Beth Israel Deaconess Medical Center (BIDMC). PT-401 is a more powerful version of erythropoietin used for the treatment of anemia in renal dialysis patients (end stage renal disease). This "Super EPO" dimer protein drug is currently in pre-clinical development and will be targeted to patients with a genetic disposition indicating their propensity to have the best clinical response.
DNAPrint is also collaborating with the H. Lee Moffitt Cancer Center on the development of two other pharmacogenomic products: OVANOME(TM), a test for predicting an ovarian cancer patient's response to TAXOL/Carboplatin treatment, and STATINOME(TM), a test for predicting adverse response to cholesterol lowering medicines known as Statins.
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
